Policy & Regulation
Infant Bacterial Therapeutics announces agreement by US FDA on design of phase III study
20 May 2019 - Infant Bacterial Therapeutics (IBT) (STO:IBTB) announced on Friday that the US FDA has informed IBT in writing that IBT has responded satisfactorily to the comments that the FDA had rega...
Inteliquet executes Cooperative R&D Agreement with the National Cancer Institute
20 May 2019 - Intelligent technology company Inteliquet reported on Monday the launch of a Cooperative Research and Development Agreement (CRADA) with the US Department of Health and Human Services an...
Bridge Biotherapeutics provides encouraging data from first-in-human study of BBT-877 for idiopathic pulmonary fibrosis
20 May 2019 - Biotech company Bridge Biotherapeutics Inc said on Friday that it has presented the interim data from the idiopathic pulmonary fibrosis (IPF) Phase I clinical study of BBT-877 at the Ame...
Victory Nutrition International Inc updates results of the metabolic enzyme N-SORB
20 May 2019 - Research company Victory Nutrition International Inc (VNI) on Friday announced the publication of the results of a randomised, double-blind, placebo-controlled study for the Safety and E...
T3D Therapeutics anticipates USD9m from NIA for Phase 2 PIONEER study in patients with Alzheimer's Disease
20 May 2019 - Drug development company T3D Therapeutics said on Monday that it expects USD9m in grants to help fund the Phase 2 clinical study of T3D-959 for treating Alzheimer's Disease (AD) .Th...
CellPoint plans to start patient recruitment for Phase 2b cardiovascular imaging study of Oncardia kits
20 May 2019 - CellPoint, a biopharmaceutical company, announced on Friday that it plans to commence patient recruitment for its Phase 2b cardiovascular imaging study in patients suffering from coronar...